---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-241943"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:48:29.209982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial

## Summary
- Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.
- Clinical data from both low-dose adult patients to be reported on mid-November earnings call after IDMC review.
- Enrollment completion in low-dose cohort (third patient) expected Q4 2023.
- First pediatric patient dosing expected Q1 2024; FDA cleared pediatric IND.
- UK MHRA CTA for pediatric patients submitted; feedback expected H2 2023.

## SEC filing metadata
- accession: 0001193125-23-241943
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/0001193125-23-241943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/d529272d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-241943
- JSON: https://secwatch.observer/filing/0001193125-23-241943.json
- Plain text: https://secwatch.observer/filing/0001193125-23-241943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.